The fourth cytoplasmic domain, the so-called C-terminal juxtamembrane segment or helix VIII, has been identified in numerous G-protein-coupled receptors and exhibits unique functional characteristics. Efforts have been devoted to studying the juxtamembrane segment in order to understand the biological importance of the segment in G-protein activation of the cannabinoid CB 1 and CB 2 receptors. Recent biochemical data revealed that the CB 1 C-terminal juxtamembrane peptide fragment CB 1 -(401-417) can directly activate the G-protein and also showed that the specificity of the signal transduction activation by the C-terminal juxtamembrane region is unique to the CB 1 receptor but not to the CB 2 receptor (Mukhopadhyay, S., and Howlett, A. C. (2001) Eur. J. Biochem. 268, 499 -505). However, there is experimental work, not yet reported, on the conformational analyses and structural comparison between the respective helix VIII segments of the two receptors. In the present study, we have examined the conformational specificities of the cytoplasmic helical domains for both cannabinoid receptors. Three-dimensional structural features of two synthetic CB 1 and CB 2 peptides, CB 1 I397-G418 and CB 2 I298-K319, respectively, in membrane mimetic DPC micelles were studied using a combined high resolution NMR and computer modeling approach. Comparisons of the NMR-determined structures of the two peptides as well as their correspondent mutant peptides revealed their conformational properties and salt bridge dissimilarity, which might help us to understand the different structural roles of the fourth cytoplasmic helices in the function and regulation of CB 1 and CB 2 receptors.The cannabinoid (CB) 1 receptor subtypes, CB 1 and CB 2, have been cloned and classified into the class A rhodopsin-like family of the seven transmembrane G-protein-coupled receptors (GPCRs) (1, 2). These subtypes have also been identified as important drug discovery targets for numerous potential therapeutic applications, including antiemetics, appetite stimulants, analgesics, glaucoma treatment, and immune suppression (3, 4). The CB 1 receptor is located in the central and peripheral nervous system (1, 5, 6), whereas the CB 2 receptor is distributed peripherally in non-neuronal tissues, particularly in immune cells (2, 6). The CB 1 receptor interacts with the pertussis toxin-sensitive G i/o family of G-proteins to inhibit adenylate cyclase (7) and to regulate N-type Ca 2ϩ channels and inwardly rectifying K ϩ channels in the central nervous system (8 -10). The CB 2 receptor is expressed in high quantities in the human spleen and tonsils and exhibits 44% amino acid identity to the CB 1 receptor throughout the whole protein. The CB2 receptor is likely involved in the signal transduction processes in the immune system (6).Studies have been carried out to understand the three-dimensional structure of the CB receptors and their mechanisms of action by using computer molecular modeling and NMR approaches (11)(12)(13)(14)(15)(16)(17). Bramblett et al. (11) fir...